Seth Rogen is the latest celebrity to team up with multi-billion capped Canopy growth

Published 29-MAR-2019 13:03 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Seth Rogen. Why did it take you so long?

Of all the people to move into the cannabis market, you think Seth Rogen would have been there quicker.

The star of Pineapple Express and producer of love ’em or hate ’em television shows (I love ’em) such as Black Monday (starring Don Cheadle takes an irreverent look at Wall St in the 1980s and is worth your time), Preacher, and Futureman has launched his own cannabis company called Houseplant.

Rogen has opened Houseplant with long-time collaborator Evan Goldberg to supply cannabis within the burgeoning Canadian market.

It comes as no surprise that the pair just happen to be working with one of the biggest listed cannabis companies in the world, the C$19 billion capped Canopy Growth Corp. (TSE:WEED).

A spokesman for Canopy commented: “Houseplant is the result of years of experience and dedication, with each element and expression thoughtfully designed to make it easier for people to learn to love cannabis as much as Houseplant does.”

As we have reported previously, Canopy is already in bed with Martha Stewart and its subsidiary, Tweed, has a long standing relationship with Snoop Dog.

Now add Rogen to the mix and Canopy has baked a pretty potent cookie.

Rogen said: “Houseplant is a passion we’ve brought to life through drive and dedication. Every decision we’ve made for the business reflects the years of education, first-hand experience and respect we have for cannabis.”

The move by celebrities into the industry can’t hurt those looking to profit from its growth.

Along with celebrities, PR companies have now jumped on the bandwagon to sell the story.

BCW (Burson Cohn & Wolfe) is a global communications agency that recently introduced a strategic consulting unit to help companies in the emerging cannabis and hemp space gain market entry, navigate policy and regulation challenges, identify and engage the cannabis consumer and communicate product benefits, all on a global scale.

It is no surprise PR is getting into the act, and again you wonder why they have been so slow to do so, given the industry’s penchant for trying to capitalise on major trends.

According to a report by Grand View Research, Inc., the global legal marijuana market is expected to reach US$146.4 billion by end of 2025. The US legal marijuana market size was estimated at US$7.06 billion in 2016 and is expected to develop at a compound annual growth rate of 24.9% from 2017 to 2025. Estimates from New Frontier Data’s Hemp Business Journal suggest the hemp derived CBD market will triple from a $390 million market in 2018 to a $1.3 billion market by 2022.

“While the cannabis industry is significant, it is really at the nascent stage of market development,” said Donna Imperato, Global CEO, BCW.

“Companies entering the space must navigate policy, operations, consumer education, marketing, and finance and capital markets – which is no easy feat.”

Of course, if your name is Seth Rogen, Martha Stewart or Snoop Dog it may be a different story.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X